Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24594818 | 0.80 | — | — | |
| SCHEMBL14181402 | 0.80 | KDM4E (0.39) | — | |
| SCHEMBL22590648 | 0.78 | LMNA (0.39) | — | |
| SCHEMBL18315391 | 0.75 | TSHR (0.33) | — | |
| SCHEMBL25556633 | 0.74 | USP2 (0.32) | — | |
| SCHEMBL13978753 | 0.73 | RECQL (0.36) | — | |
| SCHEMBL29077091 | 0.73 | TP53 (0.32) | — | |
| SCHEMBL7711981 | 0.72 | TSHR (0.42) | — | |
| SCHEMBL11217703 | 0.71 | LMNA (0.31) | — | |
| SCHEMBL11839755 | 0.71 | SLC22A6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3701971-B1 | COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3356385-B1 | 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | DEUTSCHES KREBSFORSCH (DE) | 2020-11-11 | — | — | EP | disclosed |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, SCLY, FCGR2A | KISS1R 4313/4885ANPEP 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.